Trial · NCT00436605
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
NCT00436605, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2014-01-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma. Trials, record NCT00436605. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00436605
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
- NCT number
- NCT00436605
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 39 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- dasatinib
- First posted
- 2007-02-19
- Last updated
- 2014-05-15
- Results first posted
- 2014-01-20
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria | After every 8 weeks (or 2 courses), assessed up to 4 weeks after completion of treatment | Only those patients who have measurable disease present at baseline, have received at least one course of therapy, and have had their disease re-evaluated will be considered evaluable for response. A Simon's optimum two-stage design will be used. |
| Primary | Progression-free Survival | Time from start treatment to time of progression, assessed up to 6 months | Progression will be evaluated in this study using the new international criteria proposed by the RECIST Committee. A Simon's optimum two-stage design will be used |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria | After every 8 weeks (or 2 courses), assessed up to 4 weeks after completion of treatment | participants | NUMBER | |
| PRIMARY | Progression-free Survival | Time from start treatment to time of progression, assessed up to 6 months | weeks | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria | Treatment (Kinase Inhibitor Therapy) | 2 | participants | ||
| Progression-free Survival | Treatment (Kinase Inhibitor Therapy) | 8 | Full Range 3 to 136 | weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Kinase Inhibitor Therapy) | 39 | |
| Overall Study | COMPLETED | Treatment (Kinase Inhibitor Therapy) | 36 | |
| Overall Study | NOT COMPLETED | Treatment (Kinase Inhibitor Therapy) | 3 |
Source ClinicalTrials.gov
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Treatment (Kinase Inhibitor Therapy) | 30 | 39 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment (Kinase Inhibitor Therapy) | 27 | 39 | |
| other | Pleural Effusion | Respiratory, thoracic and mediastinal disorders | Treatment (Kinase Inhibitor Therapy) | 14 | 39 | |
| other | Nausea | Gastrointestinal disorders | Treatment (Kinase Inhibitor Therapy) | 26 | 39 | |
| other | Emesis | Gastrointestinal disorders | Treatment (Kinase Inhibitor Therapy) | 9 | 39 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Kinase Inhibitor Therapy) | 14 | 39 | |
| other | Weight Loss | General disorders | Treatment (Kinase Inhibitor Therapy) | 8 | 39 | |
| other | Rash | Skin and subcutaneous tissue disorders | Treatment (Kinase Inhibitor Therapy) | 17 | 39 | |
| other | Pruritis | Skin and subcutaneous tissue disorders | Treatment (Kinase Inhibitor Therapy) | 7 | 39 | |
| other | Anorexia | General disorders | Treatment (Kinase Inhibitor Therapy) | 23 | 39 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Kinase Inhibitor Therapy) | ||
| Total, other adverse events | Treatment (Kinase Inhibitor Therapy) | 39 | 39 |
| Total, serious adverse events | Treatment (Kinase Inhibitor Therapy) | 20 | 39 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016359 | Cancer Center Support Grant | WINER, ERIC P. | YALE UNIVERSITY | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00436605
GET https://conductscience.org/api/trials/v1/NCT00436605/events?page=2